Not exact matches
The test developed can be carried out on mothers
at risk of X-linked genetic recessive diseases including
haemophilia and Duchenne muscular dystrophy and mothers
at risk of haemolytic disease of the new - born.
«These are remarkable data,» says Amit Nathwani
at University College London, who is using AAVs in potential treatments for a blood disorder called
haemophilia B. «Liver fibrosis is a major clinical problem and if these data can be reproduced clinically, the National Health Service would save billions and patients would be given a new lease of life.»
With so many therapeutic tactics moving through the preclinical pipeline, scientists and clinicians remain hopeful that
at least one will ultimately succeed, eliminating the problem of inhibitor formation for people with
haemophilia altogether.
Indeed, exposure of the protein produced by the nanoparticle - based gene therapy to the gut mucosa prevents inhibitor development and restores clotting - factor activity in mouse models of both
haemophilia A and B. «This approach really could hold big benefit for patients,» says Jörg Schüttrumpf, a transfusion - medicine specialist who led one of the studies performed
at the German Red Cross Blood Donor Service in Frankfurt.
The nanotechnology approach that is being tested for inhibitor control could also improve the
haemophilia treatment that is now
at the cutting edge of clinical research: gene therapy.
We really now have the potential to transform care for people with
haemophilia using a single treatment for people who
at the moment must inject themselves as often as every other day.
«People who live with
haemophilia today face a lifelong need for vigilant monitoring and recurrent factor concentrate infusions to prevent spontaneous, potentially life - threatening bleeds and to protect their joints,» said Katherine High, President and Head of Research and Development
at Spark Therapeutics.